A trial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time. 1 AF is associated with an increased risk of stroke, 2 heart failure, 3 and death. 4, 5 AF is more prevalent in patients with peripheral artery disease (PAD) compared with the general population. [6] [7] [8] Data from the Reduction of Atherothrombosis for Continued Health (REACH) registry have demonstrated the high co-prevalence of PAD and AF, and the additive risk of these 2 clinical syndromes. 7, 8 In the REACH registry, there was an 11.5% prevalence of AF among patients with PAD compared with an estimated prevalence of 2.3% and 5.9% in the general population aged ≥40 and ≥65 years, respectively. 8, 9 PAD is associated with incident clinical AF regardless of age, sex, race, and cardiovascular risk factors among postmenopausal women 10 and the general population. 11, 12 Although there is evidence to support an association of PAD with AF, no study has examined whether the association (as measured by the ankle-brachial index [ABI] ) is different for ABI >1.4 versus ABI <1.0. Further, it is unknown what effect the severity of PAD (as measured by the ankle-brachial index [ABI]) has on AF incidence; specifically, whether borderline ABI (>0.9-<1.0) has a similar association as ABI ≤0.9 with AF incidence.
The aim of this study was to evaluate the longitudinal association of PAD (ABI <1.0 or >1.40), including borderline ABI (>0.9-<1.0) with AF incidence among participants in the ARIC (Atherosclerosis Risk in Communities) study.
Methods
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data underlying our work can be obtained through 2 mechanisms. First, interested investigators can contact the ARIC Coordinating Center at the University of North Carolina-Chapel Hill. Details about the procedures for data request can be found online. 13 Second, most ARIC data can be also obtained from BioLINCC, a repository maintained by the National Heart, Lung, and Blood Institute. The BioLINCC website 14 includes detailed information about the available data and the process to obtain such data. Any interested researcher could obtain a de-identified, minimal data set needed to replicate or reprove the study findings pending ethical approval following any of the 2 mentioned mechanisms.
Study Population
The ARIC study has been previously described. 15 Briefly, the ARIC study is a population-based prospective study of cardiovascular disease (CVD) in a cohort of 15 792 participants aged 45 to 64 years at enrollment (1987) (1988) (1989) sampled from 4 US communities: suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi. Only blacks were recruited in Jackson. The baseline visit (visit 1) and 4 follow-up visits-1990 to 1992 (visit 2), 1993 to 1995 (visit 3), 1996 to 1998 (visit 4), and 2011 to 2013 (visit 5), included interviews, laboratory measurements, and clinical examinations, including an ECG that was centrally read for AF. Participants were also contacted annually by phone to obtain medical updates. We included participants who had ABI information, free of prevalent AF, had a readable ECG and available covariates. Participants who had race other than white or black, along with non-whites in the Minneapolis and Washington County field centers were excluded because of small numbers ( Figure 1 ). The ARIC study protocol was approved by the institutional review boards of each participating center, and informed consent was obtained from each study participant.
ABI Measurement
Details of ABI measurement in the ARIC study have been previously described. 16, 17 Briefly, resting ankle and brachial pressures were measured by a standardized protocol using a DINAMAP TM 1846 SX automated oscillometric device (Critikon, Tampa, FL). Ankle blood pressure was measured with the individual in a prone position, in only one leg, which was selected based on the fifth digit of the ARIC ID. If the number was even, the right leg was used; if the number was odd the left leg was used. Following a first manually triggered measurement to calibrate the occlusion pressure, 2 readings of ankle blood pressure were taken 5 to 8 minutes apart. Two brachial blood pressure measurements were then measured in the supine position, 5 minutes apart. The ankle-brachial index was calculated as the average of the 2 resting ankle systolic pressure readings divided by the average of the 2 resting brachial systolic pressure readings. The correlation between the duplicate blood pressure readings has been described 16 and was found to be 0.92 in the leg, and 0.90 in the arm. The mean difference between the duplicate readings was 0.5 mm Hg (95% confidence interval [CI]: 0.3-0.6) in the leg and 3.0 mm Hg (95% CI: 2.8-3.2) in the arm. The reliability of the single measure of ABI in ARIC has also been described. 18 The reliability coefficient was 0.68 (95% CI: 0.57-0.77) for the ankle blood pressure and 0.74 (95% CI: 0.62-0.83) for the brachial blood pressure. The reliability for the ABI based on single ankle and arm systolic blood pressures (SBPs) was 0.61 (95% CI: 0.50-0.70) and was similar to the estimated reliability of the ABI measured from 2 ankle pressures and 2 arm pressures (0.70).
Ascertainment of Incident AF
The methods used for AF ascertainment in ARIC have previously been described in detail. 19, 20 
Ascertainment of Covariates
Covariates were obtained at baseline and included age at study entry, sex, race, education level, ARIC field center,
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smoking status, body mass index, systolic blood pressure, diabetes mellitus, coronary heart disease, heart failure, use of antihypertensive medications, and left ventricular ejection fraction. Race was based on self-report, and combined with study center to create a 5-level variable. Hypertension was defined as use of medication to treat high blood pressure in the previous 2 weeks, and confirmed by medications brought to the visit by the participant, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg. Diabetes mellitus was defined as a self-reported physician's diagnosis of diabetes mellitus, use of diabetic medications, nonfasting serum glucose levels ≥200 mg/dL, or fasting serum glucose levels ≥126 mg/dL. Heart failure at baseline was defined as the reported use of medications to treat heart failure in the previous 2 weeks or the clinical presence of heart failure. Heart failure at follow-up visits was defined as the presence of ICD-9-CM code 428 in any hospitalization during follow-up. Prevalent coronary heart disease (CHD) was defined as self-reported, physician-diagnosed CHD or the presence of a previous myocardial infarction (MI) by ECG. Questionnaires during study visits assessed selfreported smoking status (current, former, never) and smoking amount.
Statistical Analyses
ABI measurements at ARIC visit 1 were used in this analysis. ABI was evaluated according to guideline-defined categories of PAD diagnosis: ABI values of 1.00 to 1.40 being normal, ≤0.90 abnormal, >0.9 to <1.0 borderline, and values >1.40 indicating noncompressible arteries. 21 We first explored the relationship between PAD and AF using restricted cubic splines adjusted for age, race, and sex. 22 To estimate the association of PAD with incident AF, we calculated hazard ratios (HRs) and 95% confidence intervals (CIs) using multivariable Cox proportional hazard models. Person-years at risk were calculated from ABI measurement until date of diagnosis of AF, death, loss to follow up, or end of follow up (December 2012), whichever occurred first. The first multivariable model was adjusted for age, sex, race/ARIC field center. The second model additionally adjusted for education level, smoking status, body mass index, SBP, use of antihypertensive medication, statin use, diabetes mellitus, coronary heart disease, heart failure, cigarette years among smokers, diastolic blood pressure (DBP), and height. Incidence rates per 1000 person-years were also calculated. We adjusted for age and sex because AF incidence and prevalence increase with age 1, 20 and are different between men and women. 20 We additionally adjusted for race/ARIC field center because blacks have a lower incidence of AF compared with whites, 20 therefore there are differences in incidence rates of AF in the various ARIC field centers. Subgroup analyses were performed with stratification of the cohort according to sex, race, diabetes mellitus and CHD status. We performed additional analyses evaluating the association of baseline ABI with the risk of death among individuals with incident AF. Statistical analyses were performed with SAS v 9.3 (SAS Inc, Cary, NC). Table 1 shows selected clinical and socioeconomic characteristics of study participants overall, and by PAD status. There were 8169 (55%) female participants and 3900 participants (26%) were black. Compared with ABI 1.0 to 1.40, participants with ABI <1.0 were more likely to be female and have higher prevalence of traditional atherosclerotic risk factors. There were 2288 (15%) incident AF events among 14 794 participants during a median (25th and 75th percentile) follow-up time of 23.3 (16.4-24.4) years. Age-, race-, and sex-adjusted restricted cubic spline models of the relationship between PAD (based on ABI categories) and AF are shown in Figure 2 . The restricted cubic splines supported using the clinically-relevant categories in our analyses, supported both by the population distribution in ABI values and the significant linear association with AF in those with ABI <1.0 and then the non-significant associations and linear relationships in the other 2 categories. The P value for trend was non-linear based on using the categorical variable as a continuous term. There was a U-shaped relationship, with higher hazard ratios for AF seen in ABI <1 (including borderline ABI) as well as ABI >1.4.
Results
After adjustment for age, sex, race/ARIC field center (model 1), ABI <1 was associated with a higher risk of AF compared with those with ABI 1.0 to 1.4: HR (95% CI) 1.35 (1.21-1.51). ABI >1.4 (noncompressible arteries) was not associated with increased AF risk ( Table 2 ). The association of ABI <1 with incident AF was attenuated after additional adjustment for variables in model 2, but an increased risk of AF persisted: HR (95% CI) 1.13 (1.01-1.27). A post hoc power calculation was performed to determine whether the nonsignificant association among individuals with an ABI >1.4 was related to a small sample size. With a type I error of 0.05, a sample of 379 participants in the ABI >1.4 group, a sample of 12 183 participants in the reference group, and AF incident proportion of 15% in the reference group, we had 37% and 86% power to detect a HR of 1.2 and 1.4, respectively, for incident AF. Therefore, the non-significant association between ABI >1.4 and incident AF might have been because of inadequate power. When borderline ABI was assessed as a separate category, it was also found to be associated with higher risk of AF. After adjustment for age, sex, race/field center (model 1), both ABI ≤0.9 and ABI >0.9 to <1.0 were associated with a higher risk of AF compared with ABI 1.0 to 1.4 (Table 3) 
Discussion
In this biracial middle-aged cohort with long follow-up, PAD was associated with incident AF. After adjustment for atherosclerotic risk factors, both ABI ≤0.9 and borderline ABI were associated with a 13% increase in the risk of AF. ABI >1.4 was not associated with an increased risk of AF. Among individuals with incident AF, those with borderline ABI as well as those with PAD, have an increased risk of all-cause mortality compared with those with normal ABI. These findings add to the growing body of evidence which indicates that borderline ABI is not benign.
Prior studies that have evaluated the relationship of PAD to AF have defined PAD as ABI <1.0 or >1.4. 16 evaluated the association of high ABI (≥1.4) with adverse outcomes in a high-risk population. They found that although ABI ≥1.4 was associated with an increased risk of myocardial infarction; there was no association with stroke, all-cause mortality or vascular mortality, compared with ABI 0.9 to <1.4.
The association of borderline ABI with higher incidence of AF is noteworthy. The study population was middle aged at the time of ABI measurement (mean age 54 years). Previous reports have shown that borderline ABI is associated with increased CVD risk. Menke The link between borderline ABI and CVD may be related to endothelial dysfunction in individuals with subclinical atherosclerosis. In a 2011 paper, 28 Finnish investigators evaluated endothelial function among individuals with borderline ABI. Assessment of endothelial function was performed by measuring the reactive hyperemia index at the fingertips of these individuals. The investigators detected endothelial dysfunction, defined as reactive hyperemia index <1.67 in one quarter of the subjects, and this finding did not differ based on their cardiovascular risk factors. To our knowledge, our study is the first to show that borderline ABI is an independent risk factor for another cardiovascular outcome, namely AF. Another important finding of our study was the weaker association of PAD and AF compared with what has been previously described. The WHI analysis 10 showed an HR (95% CI) 1.53 (1.37-1.72). Of 81 892 women, 8252 developed AF over a mean follow up of 9.8 years. The WHI paper, however, suffered from an important limitation: PAD was self-reported.
In the MESA analysis, 11 301 of 6568 participants developed AF over a median follow up of 8.5 years. The HR (95% CI) for the association between PAD and AF was 1.5 (1.1-2.0). Our analysis had 2288 incident AF events among 14 794 participants, during a median (25th percentile and 75th percentile) follow-up time of 23.3 (16.4-24.4) years. Overall, our analysis has a larger sample size, more than double the follow up time, and an objective assessment of PAD status. Our study has some limitations. Ankle blood pressure was measured only in one leg which may underestimate PAD prevalence since the disease is often unilateral. Thus, the associations of ABI with prevalent atherosclerotic disease may have been underestimated. Previous reports have however demonstrated that ABI measurements in ARIC have comparable reliability to ABI measured from two ankle pressures and two arm pressures. 18 Since only one measure of ABI was used in this analysis, individuals who developed PAD afterwards, may have been missed. Most of our AF cases are identified from hospitalizations, which may not account for AF managed in outpatient setting. Also, as AF is often transient, asymptomatic patients may have been missed. Therefore, there is likely an under ascertainment of incident AF cases. However, AF cases through hospitalizations in ARIC have been validated, with a sensitivity of 84% and sensitivity of 98%. 20 Despite these limitations, this study has important strengths, including the large sample size, availability of information on potential confounders, and extended follow-up.
Conclusion
In this large population-based cohort of middle-aged adults with long follow up and objective assessment of PAD, guideline-defined PAD indicated by low ABI, is a weak risk factor for AF. This includes borderline ABI. Borderline ABI is a marker of subclinical atherosclerosis, and is not benign. ABI >1.4 is not associated with an increased AF risk. The relationship of PAD and AF appears to be mostly explained by traditional atherosclerotic risk factors.
